Table 2.
Risk of cardiovascular adverse events before and after treatment with methylphenidate
| Risk period | Arrhythmias | Hypertension | Myocardial infarction | Ischemic stroke | Heart failure | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | No of patients | RR (95% CI)* | |||||
| Primary analysis | ||||||||||||||
| Unexposed | 630 | 1 | 304 | 1 | 42 | 1 | 57 | 1 | 40 | 1 | ||||
| Exposed | 234 | 1.61 (1.48 to 1.74) | 92 | 1.07 (0.94 to 1.22) | 10 | 1.33 (0.90 to 1.98) | 10 | 0.70 (0.49 to 1.01) | 4 | 0.54 (0.30 to 0.96) | ||||
| Time since initiation of methylphenidate (days) | ||||||||||||||
| 1-3 | 24 | 2.01 (1.74 to 2.31) | 6 | 1.01 (0.77 to 1.31) | 0 | NA | 1 | 1.16 (0.61 to 2.22) | 0 | NA | ||||
| 4-7 | 26 | 1.61 (1.40 to 1.84) | 11 | 1.29 (1.04 to 1.59) | 0 | NA | 0 | NA | 0 | NA | ||||
| 8-14 | 35 | 1.33 (1.17 to 1.50) | 8 | 0.56 (0.43 to 0.71) | 3 | 2.50 (1.49 to 4.20) | 3 | 1.48 (0.98 to 2.24) | 1 | 0.82 (0.38 to 1.75) | ||||
| 15-28 | 45 | 1.29 (1.16 to 1.44) | 19 | 1.03 (0.88 to 1.22) | 2 | 1.95 (1.17 to 3.23) | 0 | NA | 1 | 0.94 (0.44 to 2.00) | ||||
| 29-56 | 51 | 1.54 (1.38 to 1.71) | 18 | 0.90 (0.75 to 1.08) | 3 | 2.57 (1.65 to 4.02) | 4 | 1.00 (0.68 to 1.47) | 0 | NA | ||||
| >56 | 53 | 1.03 (0.91 to 1.15) | 30 | 1.14 (0.97 to 1.35) | 2 | 0.67 (0.33 to 1.37) | 2 | 0.38 (0.22 to 0.65) | 2 | 0.17 (0.07 to 0.43) | ||||
NA=not applicable.
*Rate ratio adjusted for age, comorbidity, and co-medication in time varying method.